Last reviewed · How we verify
Drug: latanoprost/timolol
Latanoprost/timolol is a fixed-dose combination that reduces intraocular pressure through a prostaglandin F analog (latanoprost) that increases uveoscleral outflow and a non-selective beta-blocker (timolol) that decreases aqueous humor production.
Latanoprost/timolol is a fixed-dose combination that reduces intraocular pressure through a prostaglandin F analog (latanoprost) that increases uveoscleral outflow and a non-selective beta-blocker (timolol) that decreases aqueous humor production. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Drug: latanoprost/timolol |
|---|---|
| Sponsor | Aristotle University Of Thessaloniki |
| Drug class | Prostaglandin analog/beta-blocker combination |
| Target | Prostaglandin F receptor (FP receptor) and beta-adrenergic receptors (β1 and β2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors and increases uveoscleral (unconventional) outflow of aqueous humor from the eye. Timolol is a non-selective beta-adrenergic antagonist that reduces aqueous humor production by decreasing ciliary body secretion. Together, these complementary mechanisms provide additive intraocular pressure reduction.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Headache
- Bradycardia
- Bronchospasm (in susceptible patients)
Key clinical trials
- Effect of IOP Lowering on Progressive HM (NA)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- Circadian Rhythms of Aqueous Humor Dynamics in Humans (PHASE2)
- Effect of Lowering IOP in Glaucoma Suspects With HM (NA)
- 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: latanoprost/timolol CI brief — competitive landscape report
- Drug: latanoprost/timolol updates RSS · CI watch RSS
- Aristotle University Of Thessaloniki portfolio CI